ICON PLC Stock Euronext Dublin
Stocks
ICLR
IE0005711209
Biotechnology & Medical Research
| Market Cap | 12.85B 11.24B 10.37B 9.57B 18.17B 1,225B 18.47B 124B 48.64B 604B 48.24B 47.19B 2,075B | P/E 2026 * |
23.7x | P/E 2027 * | 19.5x |
|---|---|---|---|---|---|
| Enterprise Value | 15.23B 13.32B 12.29B 11.35B 21.54B 1,453B 21.9B 147B 57.67B 716B 57.2B 55.95B 2,460B | EV / Sales 2026 * |
1.89x | EV / Sales 2027 * | 1.75x |
| Free-Float |
99.56% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: ICON PLC
| 1 day | -0.50% |
| Manager | Title | Age | Since |
|---|---|---|---|
Barry Balfe
CEO | Chief Executive Officer | 48 | 2025-09-30 |
Nigel Clerkin
DFI | Director of Finance/CFO | 53 | 2024-09-30 |
Ute Berger
CTO | Chief Tech/Sci/R&D Officer | - | 2025-05-31 |
| Director | Title | Age | Since |
|---|---|---|---|
John Climax
CHM | Chairman | 73 | 2002-10-31 |
Ciaran Murray
CHM | Chairman | 63 | 2017-02-28 |
Eugene McCague
BRD | Director/Board Member | 67 | 2017-10-03 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.50% | -8.66% | - | - | 12.85B | |
| +0.58% | +2.06% | +2.92% | +10.86% | 50.73B | |
| -2.22% | -1.25% | +385.40% | +586.81% | 39.73B | |
| -0.54% | +0.39% | +25.57% | -5.28% | 34.69B | |
| -1.36% | +0.35% | +17.88% | +55.14% | 33.21B | |
| +1.21% | -4.58% | +3.00% | +35.46% | 26.76B | |
| -1.81% | -1.48% | - | - | 16.8B | |
| +0.51% | -3.47% | +63.97% | +122.60% | 15.37B | |
| +0.23% | -0.58% | +13.76% | +21.11% | 13.78B | |
| +0.24% | -8.96% | +1,640.79% | +665.26% | 12.11B | |
| Average | -0.37% | -1.48% | +269.16% | +186.49% | 27.02B | |
| Weighted average by Cap. | -0.44% | -0.52% | +168.16% | +162.10% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 8.06B 7.05B 6.5B 6B 11.39B 769B 11.59B 77.68B 30.5B 379B 30.26B 29.6B 1,302B | 8.31B 7.27B 6.7B 6.19B 11.75B 792B 11.94B 80.09B 31.45B 390B 31.2B 30.52B 1,342B |
| Net income | 520M 455M 419M 387M 735M 49.59B 747M 5.01B 1.97B 24.43B 1.95B 1.91B 83.98B | 608M 532M 491M 453M 860M 58.01B 875M 5.86B 2.3B 28.58B 2.28B 2.23B 98.25B |
| Net Debt | 2.39B 2.09B 1.92B 1.78B 3.37B 228B 3.43B 23B 9.03B 112B 8.96B 8.76B 385B | 1.66B 1.45B 1.34B 1.24B 2.35B 158B 2.39B 16B 6.28B 77.98B 6.23B 6.1B 268B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Choose MarketScreener 
